PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Doxercalciferol→

Doxercalciferol PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
54573-75-0
PubChem CID
5281107
Molecular formula
C28H44O2
Molecular weight
412.6 g/mol
Drug class
Vitamin D2 Analog
Mechanism of action
Doxercalciferol is a synthetic vitamin D 2 analog that requires metabolic activation to form the active 1α,25-(OH) 2 D 2 metabolite, which binds to the vitamin D receptor (VDR) to result in the selective activation of vitamin D responsive pathways.
Indications / reported uses
  • Hyperparathyroidism
  • secondary hyperparathyroidism in adult patients with Stage 3 or Stage 4 chronic kidney disease (CKD) and adult patients with CKD on dialysis
  • secondary hyperparathyroidism in adult patients with chronic kidney disease (CKD) on dialysis
  • secondary hyperparathyroidism in adult patients with CKD on dialysis

Sources: FDA product labels (openFDA) · FDA product information

Identification source: PubChem record (CID 5281107). The linked PubChem record is provided for identity reference. Confirm the exact salt, hydrate, isomer, mixture, or product form against authoritative source documentation when defining the assessment scope.

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Doxercalciferol PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Doxercalciferol Permitted Daily Exposure (PDE) report (the Doxercalciferol PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Doxercalciferol Occupational Exposure Limit (OEL) report (the Doxercalciferol OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.